MSF and groups call for end to Gilead’s hepatitis C drug monopoly in Europe which blocks access

This week in Munich, the European Patent Office is hearing a legal challenge filed by groups in 17 countries in March 2017, against an unmerited patent that allows US pharmaceutical corporation Gilead Sciences to charge exorbitant prices in Europe for the key hepatitis C drug sofosbuvir

About Admin

    You May Also Like

    error: Content is protected !!